FY2024 EPS Estimates for CG Oncology, Inc. Lowered by Analyst (NASDAQ:CGON)

CG Oncology, Inc. (NASDAQ:CGON) – Analysts at Lifesci Capital decreased their FY2024 earnings per share (EPS) estimates for CG Oncology in a research report issued on Tuesday, April 23rd. Lifesci Capital analyst S. Slutsky now forecasts that the company will earn ($1.77) per share for the year, down from their previous estimate of ($1.75). The consensus estimate for CG Oncology’s current full-year earnings is ($1.59) per share. Lifesci Capital also issued estimates for CG Oncology’s FY2025 earnings at ($2.11) EPS and FY2026 earnings at ($1.22) EPS.

Several other research firms also recently weighed in on CGON. The Goldman Sachs Group began coverage on CG Oncology in a research report on Tuesday, February 20th. They set a “neutral” rating and a $42.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $75.00 price objective on shares of CG Oncology in a report on Thursday, April 4th. Morgan Stanley began coverage on CG Oncology in a report on Tuesday, February 20th. They issued an “overweight” rating and a $55.00 price objective on the stock. Finally, Cantor Fitzgerald began coverage on CG Oncology in a report on Tuesday, February 20th. They issued an “overweight” rating and a $75.00 price objective on the stock.

CG Oncology Trading Up 0.4 %

NASDAQ CGON opened at $36.20 on Thursday. The stock’s 50-day simple moving average is $40.54. CG Oncology has a twelve month low of $28.55 and a twelve month high of $50.23.

Insider Transactions at CG Oncology

In related news, major shareholder Decheng Capital Global Life Sc bought 400,000 shares of the stock in a transaction dated Monday, January 29th. The stock was acquired at an average price of $19.00 per share, for a total transaction of $7,600,000.00. Following the completion of the purchase, the insider now owns 400,000 shares in the company, valued at $7,600,000. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, major shareholder Decheng Capital Global Life Sc bought 400,000 shares of the stock in a transaction dated Monday, January 29th. The stock was acquired at an average price of $19.00 per share, for a total transaction of $7,600,000.00. Following the completion of the purchase, the insider now owns 400,000 shares in the company, valued at $7,600,000. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Hong Fang Song bought 263,157 shares of the stock in a transaction dated Monday, January 29th. The stock was bought at an average price of $19.00 per share, with a total value of $4,999,983.00. Following the purchase, the director now owns 613,928 shares of the company’s stock, valued at approximately $11,664,632. The disclosure for this purchase can be found here. Insiders have bought a total of 666,472 shares of company stock worth $12,662,968 in the last three months.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.